A Phase 1 interventional study of OPC-34712 in Healthy Adult Male, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-23.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The ratios of the geometric means of the ODT formulation to those of the reference formulation (conventional tablet) for the bioavailability variables (Cmax, AUCt, and AUC∞ of brexpiprazole (OPC-34712)).
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OPC-34712 (4 mg) orally disintegrating tablet is administered with water.
Drug: OPC-34712
OPC-34712 (4 mg) orally disintegrating tablet is administered without water.
Drug: OPC-34712
OPC-34712 (4 mg) conventional tablet is administered with water.
Drug: OPC-34712
Also known as: Brexpiprazole
Maximum Plasma Concentration (Cmax) of OPC-34712
To evaluate Cmax of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation
Time frame: Predose, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120,144, 168, 216, 264, and 312 hours postdose
Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) of OPC-34712
To evaluate AUC∞ of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation
Time frame: Predose, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, 120,144, 168, 216, 264, and 312 hours postdose
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 |
|---|---|---|---|
| Started | 6 | 6 | 6 |
| Completed | 4 | 6 | 6 |
| Not completed | 2 | 0 | 0 |
| Withdrew: Positive urine test for cotinine on day 20 or day 40 | 2 | 0 | 0 |
To evaluate Cmax of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation
| ng/mL | OPC-34712 Disintegrating Tablet With Water | OPC-34712 Disintegrating Tablet Without Water | OPC-34712 Conventional Tablet With Water |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of OPC-34712 | 47.4 ± 10.0 | 44.9 ± 13.8 | 46.1 ± 10.8 |
To evaluate AUC∞ of OPC-34712 4-mg ODT formulation relative to 4-mg conventional tablet formulation
| ng·h/mL | OPC-34712 Disintegrating Tablet With Water | OPC-34712 Disintegrating Tablet Without Water | OPC-34712 Conventional Tablet With Water |
|---|---|---|---|
| Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) of OPC-34712 | 2920 ± 1630 | 2830 ± 1270 | 2770 ± 1460 |
Collected over From the start of IMP administration throughout follow-up period (up to 22 days after the last dose of IMP). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OPC-34712 Disintegrating Tablet With Water | 0/16 (0%) | 0/16 (0%) | 8/16 (50%) |
| OPC-34712 Disintegrating Tablet Without Water | 0/18 (0%) | 0/18 (0%) | 7/18 (38.9%) |
| OPC-34712 Conventional Tablet With Water | 0/17 (0%) | 0/17 (0%) | 9/17 (52.9%) |
| Event | OPC-34712 Disintegrating Tablet With Water | OPC-34712 Disintegrating Tablet Without Water | OPC-34712 Conventional Tablet With Water |
|---|---|---|---|
| Orthostatic HypotensionVascular disorders | 4/16 | 3/18 | 7/17 |
| NauseaGastrointestinal disorders | 4/16 | 5/18 | 4/17 |
| VomitingGastrointestinal disorders | 1/16 | 1/18 | 0/17 |
| Blood Creatine Phosphokinase IncreasedInvestigations | 1/16 | 0/18 | 0/17 |
| DizzinessNervous system disorders | 1/16 | 0/18 | 0/17 |
| HeadacheNervous system disorders | 0/16 | 1/18 | 0/17 |
| Age, Continuous(years) | Sequence 1 | Sequence 2 | Sequence 3 | Total |
|---|---|---|---|---|
| Mean | 32.8 ± 5.5 | 29.7 ± 7.4 | 28.7 ± 8.0 | 30.4 ± 6.9 |
| Sex: Female, Male(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 6 | 18 |
| Race/Ethnicity, Customized(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Total |
|---|---|---|---|---|
| Asian | 6 | 6 | 6 | 18 |
| Region of Enrollment(Participants) | Sequence 1 | Sequence 2 | Sequence 3 | Total |
|---|---|---|---|---|
| Japan | 6 | 6 | 6 | 18 |
Ran from Sep 2016 to primary completion in Nov 2016, 2 months.
Results were first posted in Feb 2021, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Co., Ltd. →